Clean Yield Group Sells 292 Shares of Bristol-Myers Squibb (NYSE:BMY)

Clean Yield Group lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 9.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,947 shares of the biopharmaceutical company’s stock after selling 292 shares during the period. Clean Yield Group’s holdings in Bristol-Myers Squibb were worth $180,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. Pinney & Scofield Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $26,000. Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Transce3nd LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at about $28,000. Finally, Global Wealth Strategies & Associates raised its stake in Bristol-Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 275 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.2%

Shares of BMY stock opened at $48.42 on Friday. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The stock has a market cap of $98.54 billion, a P/E ratio of -10.95, a P/E/G ratio of 2.07 and a beta of 0.38. The company has a 50 day simple moving average of $49.34 and a two-hundred day simple moving average of $55.04.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. During the same quarter last year, the business earned ($4.40) EPS. The firm’s revenue was down 5.6% compared to the same quarter last year. On average, research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research analyst reports. Piper Sandler assumed coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 target price on the stock. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a report on Friday, April 25th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.